RNA INTERFERENCE MEDIATED INHIBITION OF CHROMOSOME TRANSLOCATION GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)

• US 20100227911A1
• Filed: 03/04/2010
• Published: 09/09/2010
• Est. Priority Date: 02/20/2002
• Status: Abandoned Application

• Current Assignee: James McSwiggen, Leonid Beigelman
• Original Assignee: James McSwiggen, Leonid Beigelman
• Inventors: Beigelman, Leonid, McSwiggen, James
• Application Number:
  US12/717,511
• Publication Number:
  US 20100227911A1
• Time in Patent Office: Days
• US Class Current: 514/44.A
• CPC Class Codes: C12N 15/1135 against oncogenes or tumor suppressor genes
• CPC Class Codes: C12N 2310/14 interfering N.A.
• CPC Class Codes: C12N 2310/321 2'-O-R Modification
• CPC Class Codes: C12N 2310/322 2'-R Modification
• CPC Class Codes: C12N 2310/3521 Methyl

Abstract

This invention relates to compounds, compositions, and methods useful for modulating chromosomal translocation gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of chromosomal translocation gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of BCR-ABL, ERG, EWS-ERG, TEL-AML1, EWS-FLI1, TLS-FUS, PAX3-FKHR, and/or AML1-ETO fusion genes.

Claims

1. A chemically modified, short interfering nucleic acid (siNA) molecule, wherein:

(a) the siNA comprises a sense strand and a separate antisense strand, each strand having one or more pyrimidine nucleotides and one or more purine nucleotides;

(b) each strand is independently 18 to 27 nucleotides in length, and together comprise a duplex having between 17 and 23 base pairs;

(c) the antisense strand is complementary to a human BCR-ABL fusion gene RNA sequence, and;

(d) a plurality of the pyrimidine nucleotides present in the sense strand are 2′

-deoxy-2′

-fluoro pyrimidine nucleotides and a plurality of the purine nucleotides present in the sense strand are 2′

-deoxy purine nucleotides.

14. The siNA molecule of claim 1, wherein the sense strand includes a terminal cap moiety at both 5′

and 3′

-ends.

19. The siNA molecule of claim 1, wherein the sense strand, the antisense strand, or both the sense strand and the antisense strand include a 31-overhang.

21. The siNA molecule of claim 1, wherein a plurality of the pyrimidine nucleotides in the antisense strand are 2′

-deoxy-2′

-fluoro pyrimidine nucleotides and a plurality of the purine nucleotides present in the antisense strand are 2′

-O-methyl purine nucleotides.

22. The siNA of claim 21, wherein the antisense strand has a phosphorothioate internucleotide linkage at the 3′

end.

23. The siNA molecule of claim 1, wherein a plurality of the pyrimidine nucleotides present in the antisense strand are 2′

-deoxy-2′

-fluoro pyrimidine nucleotides and a plurality of the purine nucleotides present in the antisense strand are 2′

-deoxy purine nucleotides.

24. The siNA molecule of claim 23, wherein the antisense strand has a phosphorothioate internucleotide linkage at the 3′

end.

25. A composition comprising the siNA molecule of claim 1 and a pharmaceutically acceptable carrier or diluent.

2-13. -13. (canceled)

15-18. -18. (canceled)

20. (canceled)